STANDARD BIOTOOLS INC. (LAB) Form 8-K — Jul 28, 2026

$LABForm 8-KItems 1.01, 7.01, 9.01Filed Jul 28, 2026, 8:20 AM ET0001140361-26-029841Original filing

Standard BioTools Inc. entered into a material definitive agreement to sell its Mass Cytometry business to Multiplex Bio for $5 million payable via a five-year promissory note, while simultaneously receiving a $30 million cash payment from Illumina to waive future royalty and earnout obligations. The Illumina payment resolves all contingent liabilities related to the prior SomaLogic acquisition and will be included in the pro forma net cash position for the pending Treeline Biosciences merger.

Key figures

Interest Rate: 6%
Purchase Price Usd: $5,000,000
Illumina Buyout Usd: $30,041,683.63
Termination Fee Usd: $1,000,000
Potential Earnout Usd: $5,000,000
Working Capital Loan Usd: $10,000,000
Maturity Years: 5
Reimbursement Cap Step1: $125,000
Reimbursement Cap Step2: $125,000

Price after filing

1 day: +10.0%7 days: +3.2%30 days: -18.0%

Close on the filing date to close N calendar days later (from $0.79). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.